Brief: Alpha Tau Announces Grant Of Expanded Radioactive License And Final Pre-Clinical Laboratory Regulatory Approval At Its Jerusalem Headquarters
03/03/2023 13:36
March 3 (Reuters) - Alpha Tau Medical Ltd DRTS.O :
* ALPHA TAU ANNOUNCES GRANT OF EXPANDED RADIOACTIVE LICENSE
AND
FINAL PRE-CLINICAL LABORATORY REGULATORY APPROVAL AT ITS
JERUSALEM HEADQUARTERS
* GOT APPROVALS FROM BOTH ISRAELI MINISTRY OF ENVIRONMENTAL
PROTECTION AND ANIMAL TESTING COUNCIL AT ISRAELI MINISTRY OF
HEALTH
* APPROVALS FOR PRE-CLINICAL RADIOACTIVE LABORATORY AT ITS
JERUSALEM HQ, TO CONDUCT PRE-CLINICAL EXPERIMENTS UTILIZING MICE
AND RATS
Source text for Eikon: ID:nGNX8mtJXl
Further company coverage: DRTS.O
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer